Boots Rehydration Treatment

1. Name Of The Medicinal Product

Replavite

Rehydration Treatment

Care Rehydration Treatment

Superdrug Blackcurrant Flavour Rehydration Treatment

Imodium Rehydration Salts

2. Qualitative And Quantitative Composition

Each sachet contains:

Dextrose Monohydrate	BP	3.580 g
Sodium Chloride	BP	0.470 g
Sodium Citrate Dihydrate	BP	0.390 g
Potassium Chloride	BP	0.300 g
Citric Acid Anhydrous	BP	0.128 g

3. Pharmaceutical Form

Granules to be reconstituted for oral administration.

4. Clinical Particulars

4.1 Therapeutic Indications

For the treatment of acute diarrhoea and the treatment and prevention of dehydration by replacing fluids and electrolytes lost through diarrhoea.

4.2 Posology And Method Of Administration

Adults, the elderly and children over 12 years:

The contents of one or two sachets to be taken after each loose motion.

Children 1 to 12 years:

The contents of one sachet to be taken after each loose motion.

Infants under 1 year:

Not to be given unless instructed by a doctor, in which case one to one and a half the usual 24 hour feed volume should be given.

During the first 24 hours of illness Replavite should replace normal feeds in bottle fed babies, gradually resuming normal feeds as the baby gets better. In breast fed babies, firstly the recommended amount of Replavite should be given and then breast fed until satisfactory.

Reconstitution

The contents of each sachet should be dissolved in 200 ml (7 fluid ounces) of fresh drinking water (adults and children). Freshly boiled and cooled water should be used for infants and when fresh water is not available. The solution should be made up immediately before use and used within one hour. If refrigerated the solution can be kept for up to 24 hours.

A doctor should be consulted if symptoms persist for longer than 24 – 48 hours.

4.3 Contraindications

Contraindicated in patients with phenylketonuria or those with hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Care is advised if used in patients with impaired liver or kidney function.

Replavite should not be given to children under 1 year except on medical advice.

Consult your doctor in all cases of infant diarrhoea.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None stated.

4.6 Pregnancy And Lactation

May be used during pregnancy and lactation as there are no known adverse effects.

4.7 Effects On Ability To Drive And Use Machines

None stated.

4.8 Undesirable Effects

None stated.

4.9 Overdose

If significant overdosage occurs, serum and electrolytes should be evaluated. Corrective measures should be carried out and levels monitored until a return to normal levels is achieved.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

The product consists of physiological salts and glucose, which are used synergistically in solution to aid rehydration. The pharmacodynamic effect is to counter the drop in the extracellular fluid volume and electrolytes in mild to moderate diarrhoea.

5.2 Pharmacokinetic Properties

None relevant.

5.3 Preclinical Safety Data

None stated.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Colloidal Anhydrous Silica BP

Aspartame (which contains Phenylalanine)

Blackcurrant Flavourings

6.2 Incompatibilities

None stated.

6.3 Shelf Life

The granules have a two year shelf life.

The reconstituted solution should be discarded after 1 hour or 24 hours if stored in a refrigerator.

6.4 Special Precautions For Storage

Store below 25°C in a dry place.

6.5 Nature And Contents Of Container

Foil laminate sachets

or

paper (outer surface layer) /polyethylene (outer layer) /aluminium foil (outer layer) /ionomer resin (inner layer) sachets

6.6 Special Precautions For Disposal And Other Handling

None stated.

7. Marketing Authorisation Holder

Wrafton Laboratories Limited

Wrafton

Braunton

North Devon

EX33 2DL.

United Kingdom

8. Marketing Authorisation Number(S)

PL 12063/0046.

9. Date Of First Authorisation/Renewal Of The Authorisation

26 November 2003.

10. Date Of Revision Of The Text

24 March 2010.